Immune response in non-small cell lung cancer treated with durvalumab after chemoradiotherapy
Looks at immune response in adults with inoperable non-small cell lung cancer receiving durvalumab.
Plain-language title generated from the registry record
Registry title: Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients
Key facts
- Where
- A Coruña, Alicante, Badalona, Barcelona, Bilbao, Ciudad Real, Ferrol, Girona, Las Palmas de Gran Canaria, Lugo, Madrid, Majadahonda, Oviedo, Santa Cruz de Tenerife, Seville, Valencia, Valladolid, and Vigo, SpainSee the 22 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with non-small cell lung cancer (NSCLC) that cannot be removed by surgery, who had no progression after chemo-radiotherapy and will get durvalumab.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Non-small cell lung cancer, unresectable stage IIIA, IIIB or IIIC, confirmed by tissue or cell tests. ECOG 0-1.
- Earlier treatment
- Had concurrent chemo-radiotherapy (cCRT) with no progression. Is going to receive durvalumab for 12 months as the next standard treatment.
- Biomarker or test result
- PDL1 above 1%.
Main reasons for not taking part
- Refuses to sign the informed consent form
- Veins cannot be punctured for blood draws
- A medical, mental or psychological condition that would stop the person completing the study or understanding the information
Read by machine on 12 November 2026.
Where in Spain
- Hospitalario Universitario A CoruñaA Coruña, SpainContact: Rosario García Campelo, MDTaking people
- Hospital General Universitario de AlicanteAlicante, SpainContact: Natividad Martínez-Banaclocha, MDTaking people
- ICO Badalona, Hospital Germans Trias i PujolBadalona, SpainContact: Ainhoa Hernández, MDTaking people
- Hospital de la Santa Creu i Sant PauBarcelona, SpainContact: Andrés Barba, MDTaking people
- Hospital Universitari Vall d'HebronBarcelona, SpainContact: Patricia Iranzo, MDTaking people
- Hospital De BasurtoBilbao, SpainContact: Mª Angeles Sala González, MDTaking people
- Hospital General Universitario de Ciudad RealCiudad Real, SpainContact: Patricia Cruz, MDTaking people
- Complejo Hospitalario Universitario Del FerrolFerrol, SpainContact: Javier Afonso Afonso, MDTaking people
- ICO Girona, Hospital Josep TruetaGirona, SpainContact: Joaquim Bosch, MDTaking people
- Hospital Universitari de Gran Canària Doctor NegrínLas Palmas de Gran Canaria, SpainContact: David Aguiar Bujanda, MDTaking people
- Hospital Universitario Lucus AugustiLugo, SpainContact: Begoña Campos, MDTaking people
- Hospital Clínico San CarlosMadrid, SpainContact: Carlos Aguado, MDTaking people
- Hospital Universitario de la PrincesaMadrid, SpainContact: Jose Miguel Sanchez Torres, MDTaking people
- Hospital Universitario Fundación Jiménez DíazMadrid, SpainContact: Manuel Dómine, MDTaking people
- Hospital Universitario La PazMadrid, SpainContact: Javier de Castro, MDTaking people
- Hospital Universitario Puerta de HierroMajadahonda, SpainContact: Mariano Provencio, MDTaking people
- Hospital Universitario Central De AsturiasOviedo, SpainContact: Sena Valcárcel González, MDTaking people
- Hospital Universitario Nuestra Señora de CandelariaSanta Cruz de Tenerife, SpainContact: Ana Cardeña Gutierrez, MDTaking people
- Hospital Virgen Del RocioSeville, SpainContact: Reyes Bernabé, MDTaking people
- Hospital Universitario Y Politecnico La FeValencia, SpainContact: Oscar Juan, MDTaking people
- Hospital Clínico Universitario de ValladolidValladolid, SpainContact: Andrea Medina del Valle, MDTaking people
- Complexo Hospitalario Universitario De VigoVigo, SpainContact: Martín Lazaro, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Fundación GECP
- Trial code
- NCT06634199
- Record updated
- 28 January 2026
- Original description
Observational, multicenter, one-arm, non-comparative study. Data will be recorded in a retrospectively manner. The study will be based on secondary data collected from patient clinical chart completed by the doctor during routine visits. The primary objective is describe the antitumor immune response generated in the context of IO (immunotherapy) treatment after cCRT in patients with unresectable NSCLC treated in real world.Read full original descriptionShow less
Study of Antitumor Immune Response Generated After Concurrent Chemo-radiotherapy (cCRT) and IO Treatment in Non-resectable Stage IIIA/B and IIIC NSCLC Patients Treated in Real World.
Observational, multicenter, one-arm, non-comparative study. Data will be recorded in a retrospectively manner. The study will be based on secondary data collected from patient clinical chart completed by the doctor during routine visits. The primary objective is describe the antitumor immune response generated in the context of IO (immunotherapy) treatment after cCRT in patients with unresectable NSCLC treated in real world.
Inclusion: Patients with histologically- or cytologically- documented NSCLC who present unresectable stage IIIA-IIIB-IIIC disease, according to 8th version of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology); ECOG 0-1; PDL1>1%; Age ≥ 18 years at time of study; Patients without progression after cCRT, that are going to receive IO treatment (Durvalumab) for 12 months as subsequent treatment as per standard clinical practice; Patient capable of proper therapeutic compliance and accessible for correct follow-up; Patients must have signed, dated and IRB/EC-approved written informed consent form in accordance with regulatory and institutional guidelines.
Exclusion: Any medical, mental, or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or understand the patient information; Patients who refuse to sign and date an IRB/IEC-approved written informed consent form; No possibility of venipuncture.